SCHEMBL2270026

SCHEMBL2270026

Cc1ccc(C(=O)Nc2c(NC(=O)CN3CCN(c4ccccc4)CC3)ccc3c2C(=O)c2ccccc2C3=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 6/20 0.48
TSHR P16473 3/20 0.48
GFER P55789 1/20 0.48
HTT P42858 3/20 0.48
KDM4E B2RXH2 3/20 0.47
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
EGFR P00533 1/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
REV1 Q9UBZ9 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GAA P10253 1/20 0.44
DRD4 P21917 2/20 0.44
DRD2 P14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270089 0.94 GFER (0.52) MEN1KMT2AATMALDH1A1TSHR
SCHEMBL2276421 0.90 MEN1 (0.48) MEN1KMT2AALDH1A1HTTKDM4E
SCHEMBL2267970 0.90 LMNA (0.53) MEN1KMT2AALDH1A1TSHRKDM4E
SCHEMBL2270132 0.89 TERT (0.53) MEN1KMT2AALDH1A1TSHRKDM4E
SCHEMBL2275626 0.89 MAPT (0.54) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL2270372 0.89 DRD2 (0.49) MEN1KMT2AALDH1A1TSHRHTT
SCHEMBL2270415 0.88 HSD17B10 (0.47) MEN1KMT2AATMALDH1A1TSHR
SCHEMBL2272135 0.88 ALDH1A1 (0.55) MEN1KMT2AALDH1A1TSHRGFER
SCHEMBL2269876 0.87 MAPT (0.43) MEN1KMT2AATMALDH1A1TSHR
SCHEMBL2269316 0.87 KMT2A (0.59) MEN1KMT2AALDH1A1TSHRGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US claimed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US claimed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA1, ANXA5, ANXA2 MEN1 485/4885KMT2A 3021/4885ATM 414/4885
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA5, ANXA1, HCCS MEN1 847/4885KMT2A 2601/4885ATM 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.